ARISTOTLE Trial
ARISTOTLE is a multicentre, phase III, randomised trial comparing standard neoadjuvant chemoradiotherapy (CRT) of oral capecitabine and radiotherapy versus standard CRT with the addition of irinotecan. 600 patients with MRI defined locally advanced, non-metastatic rectal cancer will be allocated in a 1:1 ratio to the two treatment arms. Samples collected for translational research as part of the trial: (i) archival tumour tissue blocks (from diagnostic biopsy), (ii) tumour tissue blocks and normal mucosal tissue from tumour resection (post CRT), (iii) plasma for circulating tumour DNA (ctDNA), (iv) buffy coat for germline DNA.
Existing samples:
- Malignant tumor of rectum (disorder)
Contact Information
- Email:
- ctc.aristotle@ucl.ac.uk
- Address:
-
Cancer Research UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
Greater London
W1T 4TJ
England
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A |